Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: HIV Infections
Interventions: HIV-1 Peptide Vaccine, Microparticulate Monovalent, HIV-1 Peptide Immunogen, Multivalent; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Sarcopenia
Interventions: BPM31510, Placebo; Drug · Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 65 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Nicotine Dependence
Interventions: Oral Nicotine Pouch, Smoking Cue Reactivity Task; Other · Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Eosinophilic Asthma
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 34
States / cities: Lancaster, California • Long Beach, California • Northridge, California + 28 more

Conditions: Glaucoma, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
Interventions: Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Duarte, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: chemotherapy, Radiation; Drug · Procedure
Lead sponsor: Clinical Oncology Research Associates; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Dental Plaque
Interventions: Fluoride, Triclosan, fluoride, Chlorhexidine Gluconate; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Bipolar I Disorder
Interventions: AL001, Lithium carbonate; Drug
Lead sponsor: Alzamend Neuro, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Salivary Gland Disease, Sjogren's Syndrome, Xerostomia
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 4 Years and older
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acne Vulgaris, Isotretinoin
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 6
States / cities: Concord, North Carolina • Davidson, North Carolina • Harrisburg, North Carolina + 2 more

Conditions: Cognitive Decline
Interventions: Souvenaid, Placebo; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 55 Years to 89 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Interventions: Dexamethasone 2.5 mg and Sitagliptin 100 mg, Dexamethasone 2.5 mg and placebo tablet; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: South Burlington, Vermont

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/insulin aspart, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 24
States / cities: Fresno, California • Waterbury, Connecticut • Boynton Beach, Florida + 19 more

Conditions: Acute Myeloid Leukemia
Interventions: Oral Azacitidine, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions: venipuncture, radiation therapy; Procedure · Radiation
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Tooth Stain
Interventions: Colgate® Regular Cavity Protection, Experimental Mouth Rinse, Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint; Drug · Other
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Schizophrenia
Interventions: Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc); Drug
Lead sponsor: Matt Byerly; Other
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sinus Infection, Acute Sinusitis
Interventions: amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray; Drug
Lead sponsor: Daniel Merenstein; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more

Conditions: Oral Cancer, Oropharyngeal Cancer, Head and Neck Cancer
Interventions: Empowered Survivor Online, Springboard Beyond Cancer, Survey Administration; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 89 Years
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Pulmonary Arterial Hypertension
Interventions: i.v. selexipag, oral selexipag (Uptravi); Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: La Jolla, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Osteoarthritis
Interventions: Ensure; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 55 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Interventions: Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more

Search by objective public record fields.

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia

Brain/Craving Response to Smoking Cues After Oral Nicotine Pouch Use

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study

Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome

Absolute Bioavailability Study With Bexagliflozin

Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment

Reducing the Effects of Aging on Cognition With Therapeutic Intervention of an Oral Nutrient (REACTION): A Pilot Trial

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

Oral Nutritional Optimization in Total Joint Arthroplasty

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.